Compare KIDS & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KIDS | SIGA |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.2M | 401.0M |
| IPO Year | 2016 | 2016 |
| Metric | KIDS | SIGA |
|---|---|---|
| Price | $16.69 | $4.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $24.67 | N/A |
| AVG Volume (30 Days) | 143.7K | ★ 839.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 12.77% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.32 |
| Revenue | ★ $98,049,000.00 | N/A |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $11.85 | $224.81 |
| P/E Ratio | ★ N/A | $14.69 |
| Revenue Growth | ★ 37.95 | N/A |
| 52 Week Low | $14.91 | $4.29 |
| 52 Week High | $23.70 | $9.62 |
| Indicator | KIDS | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 38.14 |
| Support Level | $15.70 | N/A |
| Resistance Level | $19.15 | $6.98 |
| Average True Range (ATR) | 0.77 | 0.19 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 47.73 | 29.77 |
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.